Ideaya Biosciences Inc (IDYA) - Total Liabilities
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has total liabilities worth $93.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ideaya Biosciences Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Ideaya Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See IDYA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Ideaya Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ideaya Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clas Ohlson AB (publ)
ST:CLAS-B
|
Sweden | Skr4.73 Billion |
|
Viva Energy Group Ltd
AU:VEA
|
Australia | AU$10.90 Billion |
|
Shandong Linuo Technical Glass Co.Ltd.
SHE:301188
|
China | CN¥792.98 Million |
|
Aerospace Auto
SHG:600151
|
China | CN¥2.15 Billion |
|
Krungthai Card Public Company Limited
BK:KTC-R
|
Thailand | ฿66.51 Billion |
|
Krungthai Card PCL
BK:KTC
|
Thailand | ฿63.35 Billion |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
USA | $4.57 Billion |
|
CESC Limited
NSE:CESC
|
India | Rs332.81 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Ideaya Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ideaya Biosciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ideaya Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual total liabilities of Ideaya Biosciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $86.39 Million | +33.02% |
| 2024-12-31 | $64.94 Million | +130.09% |
| 2023-12-31 | $28.23 Million | -26.71% |
| 2022-12-31 | $38.51 Million | -51.76% |
| 2021-12-31 | $79.83 Million | -20.16% |
| 2020-12-31 | $100.00 Million | +693.55% |
| 2019-12-31 | $12.60 Million | -91.34% |
| 2018-12-31 | $145.49 Million | +337.98% |
| 2017-12-31 | $33.22 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more